market access

News

Kadcyla finally gets OK after price cut and NICE concessions

Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.

News

Novo hopes data will boost new insulin in US and Germany

Novo Nordisk hopes that new data supporting the cardiovascular and glycaemic safety of its Tresiba long-acting insulin will prove a game-changer in the US.

Views & Analysis

New UK law to control generic drug prices - implications for...

The aims and implications of the Health Service Medical Supplies (Costs) Act 2017.

Views & Analysis

The evolving role of clinical trial data sharing

Clinical trial data sharing has massive potential for catalysing scientific innovation.

Partner Content

Partner Content

Industry experts set to transform evolving pre-approval & un...

Created in response to unprecedented global demand from patients and physicians and to provide a long-sought after alternative for the biopharma

News

Major UK market breakthrough for Keytruda in lung cancer

But funding will last only two years on CDF.

Kadcyla finally gets OK after price cut and NICE concessions

Novo hopes data will boost new insulin in US and Germany

New UK law to control generic drug prices - implications for...

The evolving role of clinical trial data sharing

Industry experts set to transform evolving pre-approval & un...

Major UK market breakthrough for Keytruda in lung cancer

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

market access

Editor's Picks